A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: Cabozantinib

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 1, 2015, Pages 37-47

  Roy, Subhajit ^a   Narang, Bawneet K ^a   Rastogi, Shiva K ^b   Rawal, Ravindra K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b Texas State University   (United States)

Author keywords

Anti angiogenic; Cabozantinib; Multiple solid tumors; Tyrosine kinase; VEGFR2

Indexed keywords

ATAZANAVIR; CABOZANTINIB; CLARITHROMYCIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; PLACEBO; RITONAVIR; SAQUINAVIR; TELITHROMYCIN; VORICONAZOLE; ANGIOGENESIS INHIBITOR; ANILIDE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; BLEEDING DISORDER; CASTRATION RESISTANT PROSTATE CANCER; CYTOTOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOCALCEMIA; JAW OSTEONECROSIS; LIVER CELL CARCINOMA; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MEDULLARY THYROID CANCER; MULTIPLE CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; THYROID CANCER; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANILIDES; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 84919683248     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140902153840     Document Type: Article

References (52)

1. Kerbel, R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis, 2000, 21, 505-515.
2. Wu, H.C.; Huang, C.T.; Chang, D.K. Anti-angiogenic therapeutic drugs for treatment of human cancer. J. Cancer Mol., 2008, 4, 37-45.
3. Cooper, C.S.; Park, M.; Blair, D.G.; Tainsky, M.A.; Huebner, K.; Croce, C.M. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature, 1983, 311, 29-33.
4. Mughal, A.; Aslam, H.M.; Sheikh, A.; Khan, A.M.H.; Saleem, S. c-Met inhibitors. Cancer Res., 2010, 70, 639-645.
5. Adjei, A.A. MET inhibitors in cancer therapy. Int. J., 2012.
6. Peruzzi, B.; Bottaro, D.P. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res., 2006, 12, 3657-3660.
7. Homsi, J.; Daud, A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control., 2007, 14, 285-294.
8. Wise, L.M.; Inder, M.K.; Real, N.C.; Stuart, G.S.; Fleming, S.B.; Mercer, A.A. The vascular endothelial growth factor (VEGF)-E encoded by ORF virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration. Cell Microbiol., 2012, 14, 1376-1390.
9. Tokunaga, Y.; Yamazaki, Y.; Morita, T. Specific distribution of VEGF-F in viperinae snake venoms: Isolation and characterization of a VEGF-F from the venom of Daboia russelli siamensis. Arch. Biochem. Biophys., 2005, 439, 241-247.
10. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther., 2011, 10, 2298-2308.
11. Sharma, T.; Dhingra, R.; Singh, S.; Sharma, S.; Tomar, P.; Malhotra, M.; R Bhardwaj, T. Aflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Mini-Rev. Med. Chem., 2013, 13, 530-540.
12. Grunewald, F.S.; Prota, A.E.; Giese, A.; Hofer, K.B. Structure– function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. BBA-Proteins Proteomics, 2010, 1804, 567-580.
13. Aggarwal, S. What's fueling the biotech engine? Nat. Biotechnol., 2007, 25, 1097-1104.
14. Koukourakis, G.V. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. Rec. Pat. Inflamm. Allergy Drug Discov., 2012, 6, 70-77.
15. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 835-844.
16. Kane, R.C.; Farrell, A.T.; Saber, H.; Tang, S.; Williams, G.; Jee, J.M.; Liang, C.; Booth, B.; Chidambaram, N.; Morse, D. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res., 2006, 12, 7271-7278.
17. Thornton, K.; Kim, G.; Maher, V.E.; Chattopadhyay, S.; Tang, S.; Moon, Y.J.; Song, P.; Marathe, A.; Balakrishnan, S.; Zhu, H. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin. Cancer Res., 2012, 18, 3722-3730.
18. Commander, H.; Whiteside, G.; Perry, C. Vandetanib. Drugs, 2011, 71, 1355-1365.
19. Goodman, V.L.; Rock, E.P.; Dagher, R.; Ramchandani, R.P.; Abraham, S.; Gobburu, J.V.; Booth, B.P.; Verbois, S.L.; Morse, D.E.; Liang, C.Y. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res., 2007, 13, 1367-1373.
20. Kwitkowski, V.E.; Prowell, T.M.; Ibrahim, A.; Farrell, A.T.; Justice, R.; Mitchell, S.S.; Sridhara, R.; Pazdur, R. FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist, 2010, 15, 428-435.
21. Chung, A.S.; Kowanetz, M.; Wu, X.; Zhuang, G.; Ngu, H.; Finkle, D.; Komuves, L.; Peale, F.; Ferrara, N. Differential drug classspecific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol., 2012, 227, 404-416.
22. Carmichael, C.; Lau, C.; Josephson, D.Y.; Pal, S.K. Comprehensive overview of axitinib development in solid malignancies: Focus on metastatic renal cell carcinoma. Clin. Adv. Hematol. Oncol., 2012, 10, 307-314.
23. Bukowski, R.M.; Yasothan, U.; Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov.,2010, 9, 17-18.
24. Monk, B.J.; Lopez, L.M.; Zarba, J.J.; Oaknin, A.; Tarpin, C.; Termrungruanglert, W.; Alber, J.A.; Ding, J.; Stutts, M.W.; Pandite, L.N. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J. Clin. Oncol., 2010, 28, 3562-3569.
25. Gaya, A.; Tse, V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat. Rev., 2012, 38, 484-493.
26. Available at: http://www.accessdata.fda.gov/drugsatfdadocs/label/2012/203756lbl.pdf (Aug 21, 2014).
27. Stewart, M.W.; Grippon, S.; Kirkpatrick, P. Aflibercept. Nat. Rev. Drug Discov.,2012, 11, 269-270.
28. Lederman, L. Ponatinib: New option for the treatment of adults with CML or Ph+ all that is resistant or intolerant to previous therapy with tyrosine kinase inhibitors. Am. Health Drug Benefits, 2013, 6, 24.
29. Ou, S.H.I. Crizotinib: A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Dev. Ther.,2011, 5, 471.
30. Ou, S.H.I. Crizotinib: A drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Exp. Rev. Anticancer Ther., 2012, 12, 151-162.
31. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Welsh, L.C. VEGF receptor signalling? In control of vascular function. Nat. Rev. Mol. Cell Biol., 2006, 7, 359-371.
32. Hage, C.; Rausch, V.; Giese, N.; Giese, T.; Schonsiegel, F.; Labsch, S.; Nwaeburu, C.; Mattern, J.; Gladkich, J.; Herr, I. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis., 2013, 4, e627.
33. St, C.B.A.; Lamb, P.; Gallagher, W.P. Malate salt of n-4-{[6, 7-bis (methyloxy) quin0lin-4-yl] oxy} phenyl-n'-(4-fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer. In WO Patent App. PCT/US2010/021, 194: 2010.
34. Kurzrock, R.; Sherman, S.I.; Ball, D.W.; Forastiere, A.A.; Cohen, R.B.; Mehra, R.; Pfister, D.G.; Cohen, E.E.; Janisch, L.; Nauling, F. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol., 2011, 29, 2660-2666.
35. Solimando, J., Dominic A; Ho, K.V.; Waddell, J.A. Drug Monographs: Cabozantanib and Omacetaxine. Hosp. Pharmacy, 2013, 48, 373-377.
36. Zhang, Y.; Guessous, F.; Kofman, A.; Schiff, D.; Abounader, R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. Drugs, 2010, 13, 112.
37. Torres, K.E.; Zhu, Q.S.; Bill, K.; Lopez, G.; Ghadimi, M.P.; Xie, X.; Young, E.D.; Liu, J.; Nguyen, T.; Bolshakov, S. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin. Cancer Res., 2011, 17, 3943-3955.
38. Roland, C.L.; Dineen, S.P.; Lynn, K.D.; Sullivan, L.A.; Dellinger, M.T.; Sadegh, L.; Sullivan, J.P.; Shames, D.S.; Brekken, R.A. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther., 2009, 8, 1761-1771.
39. Munshi, N.; Jeay, S.; Li, Y.; Chen, C.R.; France, D.S.; Ashwell, M.A.; Hill, J.; Moussa, M.M.; Leggett, D.S.; Li, C.J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther., 2010, 9, 1544-1553.
40. Gupta, A.V.; Troxel, A.B.; Nellore, A.; Puttaswamy, K.; Redlinger, M.; Ransone, K.; Mandel, S.J.; Flaherty, K.T.; Loevner, L.A.; O'Dwyer, P.J. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol., 2008, 26, 4714-4719.
41. Robinson, B.G.; Ares, L.P.; Krebs, A.; Vasselli, J.; Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocr. Metab., 2010, 95, 2664-2671.
42. Wells, S.; Gosnell, J.; Gagel, R.; Moley, J.; Pfister, D.; Sosa, J.; Skinner, M.; Krebs, A.; Hou, J.; Schlumberger, M. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J. Clin. Oncol., 2007, 25, 6018.
43. Schlumberger, M.J.; Elisei, R.; Bastholt, L.; Wirth, L.J.; Martins, R.G.; Locati, L.D.; Jarzab, B.; Pacini, F.; Daumerie, C.; Droz, J.P. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol., 2009, 27, 3794-3801.
44. Rini, B.I.; Wilding, G.; Hudes, G.; Stadler, W.M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P.C.; Wood, L.; Dutcher, J.P. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27, 4462-4468.
45. Hussain, M.; Smith, M.; Sweeney, C.; Corn, P.; Elfiky, A.; Gordon, M.; Haas, N.; Harzstark, A.; Kurzrock, R.; Lara Jr, P. Cabozantinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): Results from a Phase 2 randomized discontinuation trial. J. Clin. Oncol., 2011, 29, 1-29.
46. Gordon, M.; Vogelzang, N.; Schoffski, P.; Daud, A.; Spira, A.; O'Keeffe, B.; Rafferty, T.; Lee, Y.; Berger, R.; Shapiro, G. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2011, 29, 196.
47. Bergsland, E.K. In The evolving landscape of neuroendocrine tumors, Seminars in oncology, 2013; Elsevier: 2013; pp 4-22.
48. Verslype, C.; Cohn, A.L.; Kelley, R.K.; Yang, T.S.; Su, W.C.; Ramies, D.A.; Lee, Y.; Shen, X.; Cutsem, E.V. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J. Clin. Oncol., 2012, 30, 4007.
49. Hellerstedt, B.A.; Edelman, G.; Vogelzang, N.J.; Kluger, H.M.; Yasenchak, C.A.; Shen, X.; Ramies, D.A.; Gordon, M.S.; Jr, P.L. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a Phase 2 randomized discontinuation trial (RDT). Cancer (NSCLC), 2012, 6, 7.
50. Nagilla, M.; Brown, R.L.; Cohen, E.E. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv. Ther., 2012, 29, 925-934.
51. Schoffski, P.; Elisei, R.; Muller, S.; Brose, M.S.; Shah, M.H.; Licitra, L.F. In An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid cancer (MTC) patients (pts) with documented RECIST progression at baseline. J. Clin. Oncol., 2012, p 5508.
52. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01522443 (Aug 21, 2014).